Zydus Lifesciences Limited has announced that its indirect wholly-owned subsidiary, Amplitude SAS, has successfully acquired 100% of the share capital of the French firm FBC Medical. Finalized on April 30, 2026, the all-cash deal is valued at Euro 700,000. This strategic acquisition is designed to internalize medical equipment distribution capabilities, aiming to eliminate third-party sales commissions and reduce long-term operational costs.
Strategic Acquisition in France
Amplitude SAS, an indirect wholly-owned subsidiary of Zydus Lifesciences, has officially completed the acquisition of FBC Medical, a simplified joint-stock company based in France. The transaction, which resulted in a 100% ownership transfer, was finalized on April 30, 2026, through a total cash consideration of Euro 700,000.
Business Integration and Objectives
FBC Medical specializes in the distribution of medical equipment and has served as an exclusive sales agent for Amplitude in French departments 35, 22, 29, and 56 since its incorporation in 2016. By bringing this entity in-house, the company aims to internalize commercial functions that were previously outsourced to third-party agents. This move is expected to streamline operations by removing business-development fees and commissions, ultimately driving down long-term distribution expenses.
Financial Overview of the Target Entity
The acquisition target has maintained a stable revenue profile over the past three fiscal years. According to audited financial statements, FBC Medical reported a turnover of Euro 924,000 in FY2023, Euro 951,000 in FY2024, and Euro 935,000 in FY2025. With this acquisition, Zydus Lifesciences integrates 5,000 fully paid-up equity shares into its international operations network.
Source: BSE
